Skip to main content

Table 2 Actigraphy endpoints (full analysis set)

From: Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)

Endpoint Treatment Baseline value, mean Change from baseline
LS mean (95 % CI)aor mean (SD)b LS mean difference (95 % CI)aor mean (SD)b
Duration of at least moderate activity per day, minutes IND/GLY 125 -6.9 (-13.4, -0.4) 4.4 (-3.3, 12.1; p = 0.264)
Placebo 130 -11.3 (-17.9, -4.6)
Average number of steps per day IND/GLY 5602 31 (1662.4) 358 (2458.0; p = 0.029)
Placebo 5849 -321 (1647.6)
Average physical activity IND/GLY 1.49 0.01 (0, 0.03) 0.02 (0, 0.04); p = 0.019
Placebo 1.50 -0.01 (-0.03, 0.01)
  1. aDuration of at least moderate activity and average physical activity
  2. bAverage number of steps per day